# EDGAR Filing Document

**Accession Number:** 0001514183
**File Stem:** 0001213900-26-070212
**Filing Date:** 2026-6
**Character Count:** 8863
**Document Hash:** d21e53433825f1e272aa96b55b1a6299
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-070212.hdr.sgml**: 20260618

**ACCESSION NUMBER**: 0001213900-26-070212

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260617

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260618

**DATE AS OF CHANGE**: 20260618

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Silo Pharma, Inc.
- **CENTRAL INDEX KEY:** 0001514183
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 462137136
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41512
- **FILM NUMBER:** 261104027

**BUSINESS ADDRESS:**
- **STREET 1:** 677 N. WASHINGTON BLVD
- **CITY:** SARASOTA
- **STATE:** FL
- **ZIP:** 34236
- **BUSINESS PHONE:** (718) 400-9031

**MAIL ADDRESS:**
- **STREET 1:** 677 N. WASHINGTON BLVD
- **CITY:** SARASOTA
- **STATE:** FL
- **ZIP:** 34236

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Uppercut Brands, Inc.
- **DATE OF NAME CHANGE:** 20190808

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Point Capital, Inc.
- **DATE OF NAME CHANGE:** 20130130

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Gold Swap Inc
- **DATE OF NAME CHANGE:** 20110301

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 17, 2026**

**Silo Pharma, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **001-41512** | **27-3046338** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (IRS Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **677 N. Washington Boulevard**<br> **Sarasota, FL** | **34236** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(718) 400-9031**

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Rule 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of exchange on which registered** |
| Common Stock, par value $0.0001 per share | SILO | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01 Other Events.**

As previously disclosed, on June 27, 2025, Silo Pharma, Inc. (the "Company") received a letter from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, based upon the closing bid price of the Company's common stock for the thirty (30) consecutive business days ended June 25, 2025, the Company no longer satisfied the requirement to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2).

On June 17, 2026, the Company received a letter from Nasdaq stating that its Staff has determined the closing bid price of the Company's common stock has been at $1.00 per share or greater from June 3, 2026 and June 16, 2026. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers this matter closed.

On June 18, 2026, the Company issued a press release announcing it has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release of Silo Pharma, Inc. dated June 18, 2026](ea029533901ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **SILO PHARMA, INC.** | **SILO PHARMA, INC.** |
| Date: June 18, 2026 | By: | /s/ Eric Weisblum |
|  |  | Eric Weisblum |
|  |  | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement**

SARASOTA, FLA., June 18, 2026 — Silo Pharma (Nasdaq: SILO) ("Silo" or "the Company"), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC informing the Company that, as of June 17, 2026, it has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). Silo's common stock continues to trade on the Nasdaq Capital Market, and the matter is now closed.

"We appreciate the loyalty and continuing support from our investors for our business strategies aimed at creating long-term value for stockholders. Looking ahead, we remain confident about our progress toward a first-in-human clinical trial of our lead drug SPC-15 targeting PTSD and successfully advancing our AI agents platform QwikAgents," said Eric Weisblum, Chief Executive Officer of Silo Pharma.

**About Silo Pharma, Inc.**

Silo Pharma is a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company's portfolio includes innovative programs such as SPC-15 for post-traumatic stress disorder (PTSD), SP-26 for fibromyalgia and chronic pain, and a preclinical asset targeting Alzheimer's disease. Silo's research is conducted in collaboration with leading universities and laboratories. silopharma.com

**Forward Looking Statements**

This news release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words "could", "believe", "anticipate", "intend", "estimate", "expect", "may", "continue", "predict", "potential", and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements about the intended use of proceeds from the offering, changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company's technology platforms, retaining and expanding the Company's customer base, fluctuations in consumer spending on the Company's products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.

**Contact**

(800) 705-0120<br> investors@silopharma.com